|
|||||
|
|
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy |
|
| Authors: | Karim R. Saab MD Meghan J. Mooradian MD Daniel Y. Wang MD Jeewon Chon MD Cathy Y. Xia MD Angelica Bialczak BS Kelly T. Abbate BS Alexander M. Menzies MD PhD Douglas B. Johnson MD Ryan J. Sullivan MD Alexander N. Shoushtari MD |
| Affiliation: | 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York;2. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts;3. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee;4. Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia;5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;6. Department of Medicine, Melanoma Institute Australia, Sydney, New South Wales, Australia The University of Sydney, Sydney, New South Wales, Australia |
| Abstract: | |
| Keywords: | BRAF efficacy MEK melanoma programmed cell death protein 1 (PD-1) toxicity |